Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16

Biochemical Journal - Tập 474 Số 5 - Trang 699-713 - 2017
Sarah E. Dixon-Clarke1, Saifeldin N. Shehata2,3, T. Krojer1, Timothy Sharpe1, F. von Delft4,5,1, Kei Sakamoto2,3, Alex N. Bullock1
1Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K.
2Nestlé Institute of Health Sciences SA, EPFL Innovation Park, Bâtiment G, 1015 Lausanne, Switzerland
3School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
4Department of Biochemistry, University of Johannesburg, Auckland Park, 2006, South Africa
5Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K.

Tóm tắt

CDK16 (also known as PCTAIRE1 or PCTK1) is an atypical member of the cyclin-dependent kinase (CDK) family that has emerged as a key regulator of neurite outgrowth, vesicle trafficking and cancer cell proliferation. CDK16 is activated through binding to cyclin Y via a phosphorylation-dependent 14-3-3 interaction and has a unique consensus substrate phosphorylation motif compared with conventional CDKs. To elucidate the structure and inhibitor-binding properties of this atypical CDK, we screened the CDK16 kinase domain against different inhibitor libraries and determined the co-structures of identified hits. We discovered that the ATP-binding pocket of CDK16 can accommodate both type I and type II kinase inhibitors. The most potent CDK16 inhibitors revealed by cell-free and cell-based assays were the multitargeted cancer drugs dabrafenib and rebastinib. An inactive DFG-out binding conformation was confirmed by the first crystal structures of CDK16 in separate complexes with the inhibitors indirubin E804 and rebastinib, respectively. The structures revealed considerable conformational plasticity, suggesting that the isolated CDK16 kinase domain was relatively unstable in the absence of a cyclin partner. The unusual structural features and chemical scaffolds identified here hold promise for the development of more selective CDK16 inhibitors and provide opportunity to better characterise the role of CDK16 and its related CDK family members in various physiological and pathological contexts.

Từ khóa


Tài liệu tham khảo

Malumbres, 2009, Cyclin-dependent kinases: a family portrait, Nat. Cell Biol., 11, 1275, 10.1038/ncb1109-1275

Malumbres, 2014, Cyclin-dependent kinases, Genome Biol., 15, 122, 10.1186/gb4184

Mikolcevic, 2012, Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis, Mol. Cell Biol., 32, 868, 10.1128/MCB.06261-11

Zi, 2015, CCNYL1, but Not CCNY, cooperates with CDK16 to regulate spermatogenesis in mouse, PLoS Genet., 11, e1005485, 10.1371/journal.pgen.1005485

Shehata, 2015, Cyclin Y phosphorylation- and 14-3-3-binding-dependent activation of PCTAIRE-1/CDK16, Biochem. J., 469, 409, 10.1042/BJ20150486

Mikolcevic, 2012, Orphan kinases turn eccentric: a new class of cyclin Y-activated, membrane-targeted CDKs, Cell Cycle, 11, 3758, 10.4161/cc.21592

Graeser, 2002, Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells, J. Cell Sci., 115, 3479, 10.1242/jcs.115.17.3479

Li, 2014, 14-3-3 binding to cyclin Y contributes to cyclin Y/CDK14 association, Acta Biochim. Biophys. Sin., 46, 299, 10.1093/abbs/gmu005

Cole, 2009, PCTK proteins: the forgotten brain kinases?, Neuro-Signals, 17, 288, 10.1159/000231895

Ou, 2010, Two cyclin-dependent kinase pathways are essential for polarized trafficking of presynaptic components, Cell, 141, 846, 10.1016/j.cell.2010.04.011

Liu, 2006, Pctaire1 phosphorylates N-ethylmaleimide-sensitive fusion protein: implications in the regulation of its hexamerization and exocytosis, J. Biol. Chem., 281, 9852, 10.1074/jbc.M513496200

Palmer, 2005, PCTAIRE protein kinases interact directly with the COPII complex and modulate secretory cargo transport, J. Cell Sci., 118, 3839, 10.1242/jcs.02496

Tang, 2006, An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport, Proc. Natl Acad. Sci. U.S.A., 103, 2087, 10.1073/pnas.0507660103

Chen, 2012, Brain-selective kinase 2 (BRSK2) phosphorylation on PCTAIRE1 negatively regulates glucose-stimulated insulin secretion in pancreatic beta-cells, J. Biol. Chem., 287, 30368, 10.1074/jbc.M112.375618

Shimizu, 2014, Pctaire1/Cdk16 promotes skeletal myogenesis by inducing myoblast migration and fusion, FEBS Lett., 588, 3030, 10.1016/j.febslet.2014.05.060

Yanagi, 2015, PCTAIRE1/PCTK1/CDK16: a new oncotarget?, Cell Cycle, 14, 463, 10.1080/15384101.2015.1006539

Yanagi, 2014, PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells, Cancer Res., 74, 5795, 10.1158/0008-5472.CAN-14-0872

Yanagi, 2014, PCTAIRE1 regulates p27 stability, apoptosis and tumor growth in malignant melanoma, Oncoscience, 1, 624, 10.18632/oncoscience.86

C´wiek, 2015, RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification, Oncotarget, 6, 116, 10.18632/oncotarget.2699

Yanagi, 2016, Lipid nanoparticle-mediated siRNA transfer against PCTAIRE1/PCTK1/Cdk16 inhibits in vivo cancer growth, Mol. Ther. Nucleic Acids, 5, e327, 10.1038/mtna.2016.40

Niesen, 2007, The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability, Nat. Protoc., 2, 2212, 10.1038/nprot.2007.321

Shehata, 2012, Analysis of substrate specificity and cyclin Y binding of PCTAIRE-1 kinase, Cell. Signal., 24, 2085, 10.1016/j.cellsig.2012.06.018

Huber, 2015, Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling, Nat. Methods, 12, 1055, 10.1038/nmeth.3590

Molina, 2013, Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay, Science, 341, 84, 10.1126/science.1233606

Kabsch, 2010, Xds, Acta Crystallogr. Sect. D, Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337

Evans, 2007, SCALA—Scale Together Multiple Observations of Reflections, 3.3.0 edn

McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206

Bricogne, 2016, BUSTER Version 2.8.0

Emsley, 2010, Features and development of Coot, Acta Crystallogr. Sect. D, Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493

Chen, 2010, Molprobity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. Sect. D, Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073

Leslie, 2007, Evolving Methods for Macromolecular Crystallography, 41, 10.1007/978-1-4020-6316-9_4

Evans, 2013, How good are my data and what is the resolution?, Acta Crystallogr. Sect. D, Biol. Crystallogr., 69, 1204, 10.1107/S0907444913000061

Murshudov, 2011, REFMAC5 for the refinement of macromolecular crystal structures, Acta Crystallogr. Sect. D, Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314

Cowtan, 2008, Fitting molecular fragments into electron density, Acta Crystallogr. Sect. D, Biol. Crystallogr., 64, 83, 10.1107/S0907444907033938

Schrödinger LLC . (Version 1.2r3pre) The PyMOL Molecular Graphics System.

Fedorov, 2007, A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases, Proc. Natl Acad. Sci. U.S.A., 104, 20523, 10.1073/pnas.0708800104

Elkins, 2016, Comprehensive characterization of the published kinase inhibitor set, Nat. Biotechnol., 34, 95, 10.1038/nbt.3374

Chaikuad, 2014, Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies, Biochem. J., 459, 59, 10.1042/BJ20131399

Chan, 2011, Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036, Cancer Cell, 19, 556, 10.1016/j.ccr.2011.03.003

Zhang, 2015, RAF inhibitors that evade paradoxical MAPK pathway activation, Nature, 526, 583, 10.1038/nature14982

Bourne, 1996, Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1, Cell, 84, 863, 10.1016/S0092-8674(00)81065-X

Jiang, 2009, Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1, FEBS Lett., 583, 2171, 10.1016/j.febslet.2009.06.010

Deng, 2014, Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor, Bioorg. Med. Chem. Lett., 24, 199, 10.1016/j.bmcl.2013.11.041

Alexander, 2015, Type II inhibitors targeting CDK2, ACS Chem. Biol., 10, 2116, 10.1021/acschembio.5b00398

Waizenegger, 2016, A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation, Mol. Cancer Ther., 15, 354, 10.1158/1535-7163.MCT-15-0617

Tarricone, 2001, Structure and regulation of the CDK5-p25(nck5a) complex, Mol. Cell, 8, 657, 10.1016/S1097-2765(01)00343-4

Huang, 2007, Structure of the Pho85-Pho80 CDK-cyclin complex of the phosphate-responsive signal transduction pathway, Mol. Cell, 28, 614, 10.1016/j.molcel.2007.09.013

Russo, 1996, Structural basis of cyclin-dependent kinase activation by phosphorylation, Nat. Struct. Biol., 3, 696, 10.1038/nsb0896-696

Liu, 2016, Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway, Tumour Biol., 37, 10161, 10.1007/s13277-016-4818-3

Yue, 2011, Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis, Clin. Lung Cancer, 12, 43, 10.3816/CLC.2011.n.006

Miyagaki, 2012, Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma, Br. J. Cancer, 106, 947, 10.1038/bjc.2012.35

Sun, 2014, PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma, Biochem. Biophys. Res. Commun., 449, 163, 10.1016/j.bbrc.2014.05.002

Yang, 2015, PFTK1 promotes gastric cancer progression by regulating proliferation, migration and invasion, PLoS ONE, 10, e0140451, 10.1371/journal.pone.0140451

Şahin, 2014, siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers, Biomaterials, 35, 9382, 10.1016/j.biomaterials.2014.07.029

Xu, 2009, Lentivirus-mediated knockdown of cyclin Y (CCNY) inhibits glioma cell proliferation, Oncol. Res., 18, 359, 10.3727/096504010X12644422320582

Yan, 2016, RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth, Oncol. Rep., 36, 2793, 10.3892/or.2016.5126

Fan, 2015, Knockdown of PFTK1 inhibits the migration of glioma cells, J. Mol. Neurosci., 57, 257, 10.1007/s12031-015-0600-z

Liu, 2016, Knockdown of PFTK1 expression by RNAi inhibits the proliferation and invasion of human non-small lung adenocarcinoma cells, Oncol. Res., 24, 181, 10.3727/096504016X14635761799038

Ayaz, 2016, Conformational adaption may explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type I CDK inhibitor with kinetic selectivity for CDK2 and CDK9, ACS Chem. Biol., 11, 1710, 10.1021/acschembio.6b00074

Thông tin
Thông tin xuất bản

Biochemical Journal

Tập 474 Số 5

699-713

Thông tin tác giả